Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 2/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.48 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964440 | 0.92 | KISS1R (0.48) | CTSLKISS1RQRFPR | |
| SCHEMBL20964460 | 0.91 | MMP2 (0.53) | CTSLMMP2GHSRKISS1ROPRK1 | |
| SCHEMBL20964470 | 0.90 | MMP2 (0.53) | MMP2KISS1R | |
| SCHEMBL20964474 | 0.90 | MMP2 (0.50) | CTSLMMP2GHSROPRK1UTS2R | |
| SCHEMBL29972565 | 0.89 | CTSL (0.51) | CTSLMMP2GHSRQRFPROPRK1 | |
| SCHEMBL20964476 | 0.89 | QRFPR (0.49) | CTSLGHSRKISS1RQRFPRPRSS1 | |
| SCHEMBL20964448 | 0.88 | QRFPR (0.48) | CTSLKISS1RQRFPR | |
| SCHEMBL20964477 | 0.88 | CTSL (0.48) | CTSLMMP2GHSRKISS1ROPRK1 | |
| SCHEMBL29389091 | 0.87 | MMP2 (0.51) | CTSLMMP2GHSROPRK1UTS2R | |
| SCHEMBL30402753 | 0.87 | GNPAT (0.58) | MMP2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | CTSL 318/4885MMP2 2707/4885GHSR 14/4885 |
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | CTSL 318/4885MMP2 2707/4885GHSR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.